Lucid-21-302
Phase 1- Indications
- Multiple sclerosis
Company intelligence / Profile preview
Huge Biopharma
Australiamarketscreener.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
On March 26, 2024, Huge Biopharma entered into an agreement with Ingenu to conduct "A Phase 1, Randomised, Double-Blind" clinical trial[8]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Ingenu (clinical trial agreement as of March 26, 2024)
Beyond the preview
Go deeper on Huge Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huge Biopharma.